Reclassification, Thromboembolic, and Major Bleeding Outcomes Using Different mates of Renal Function in Anticoagulated Patients With Atrial Fibrillation: Insights From the PREFER-in-AF and PREFER-in-AF Prolongation Registries

Miklos Rohla; Ladislav Pecen; Roberto Cemin; Giuseppe Rocco Salvatore Patti; Jolanta M Siller-Matula; Renate B Schnabel; Kurt Huber; Paulus Kirchhof; Raffaele De Caterina

doi:10.1161/CIRCOUTCOMES.120.006852

Reclassification, Thromboembolic, and Major Bleeding Outcomes Using Different mates of Renal Function in Anticoagulated Patients With Atrial Fibrillation: Insights From the PREFER-in-AF and PREFER-in-AF Prolongation Registries

Miklos Rohla
, Ladislav Pecen
, Roberto Cemin
, Giuseppe Rocco Salvatore Patti
, Jolanta M Siller-Matula
, Renate B Schnabel
, Kurt Huber
, Paulus Kirchhof
, Raffaele De Caterina

Dipartimento di Medicina Traslazionale

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

Abstract

The Cockcroft-Gault formula is recommended to determine a renal indication for dose reduction of dabigatran, edoxaban, and rivaroxaban. Nephrology guidelines now recommend the Modification of Diet in Renal Disease (MDRD) and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formulae as more accurate estimates of glomerular filtration rate.

Lingua originale	Inglese
Rivista	Circulation: Cardiovascular Quality and Outcomes
DOI	https://doi.org/10.1161/CIRCOUTCOMES.120.006852
Stato di pubblicazione	Pubblicato - 2021

Keywords

atrial fibrillation
chronic kidney disease
dabigatran
edoxaban
glomerular filtration rate

Accesso al documento

10.1161/CIRCOUTCOMES.120.006852

http://hdl.handle.net/11579/126749

Altri file e collegamenti

handle

Fingerprint

Entra nei temi di ricerca di 'Reclassification, Thromboembolic, and Major Bleeding Outcomes Using Different mates of Renal Function in Anticoagulated Patients With Atrial Fibrillation: Insights From the PREFER-in-AF and PREFER-in-AF Prolongation Registries'. Insieme formano una fingerprint unica.

Cita questo

Rohla, M., Pecen, L., Cemin, R., Patti, G. R. S., Siller-Matula, J. M., Schnabel, R. B., Huber, K., Kirchhof, P., & De Caterina, R. (2021). Reclassification, Thromboembolic, and Major Bleeding Outcomes Using Different mates of Renal Function in Anticoagulated Patients With Atrial Fibrillation: Insights From the PREFER-in-AF and PREFER-in-AF Prolongation Registries. Circulation: Cardiovascular Quality and Outcomes. https://doi.org/10.1161/CIRCOUTCOMES.120.006852

@article{1e70a5a2319e4fb1a870d38468e7f3f4,

title = "Reclassification, Thromboembolic, and Major Bleeding Outcomes Using Different mates of Renal Function in Anticoagulated Patients With Atrial Fibrillation: Insights From the PREFER-in-AF and PREFER-in-AF Prolongation Registries",

abstract = "The Cockcroft-Gault formula is recommended to determine a renal indication for dose reduction of dabigatran, edoxaban, and rivaroxaban. Nephrology guidelines now recommend the Modification of Diet in Renal Disease (MDRD) and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formulae as more accurate estimates of glomerular filtration rate.",

keywords = "atrial fibrillation, chronic kidney disease, dabigatran, edoxaban, glomerular filtration rate, atrial fibrillation, chronic kidney disease, dabigatran, edoxaban, glomerular filtration rate",

author = "Miklos Rohla and Ladislav Pecen and Roberto Cemin and Patti, \{Giuseppe Rocco Salvatore\} and Siller-Matula, \{Jolanta M\} and Schnabel, \{Renate B\} and Kurt Huber and Paulus Kirchhof and \{De Caterina\}, Raffaele",

year = "2021",

doi = "10.1161/CIRCOUTCOMES.120.006852",

language = "English",

journal = "Circulation: Cardiovascular Quality and Outcomes",

issn = "1941-7713",

publisher = "Lippincott Williams and Wilkins",

}

Rohla, M, Pecen, L, Cemin, R, Patti, GRS, Siller-Matula, JM, Schnabel, RB, Huber, K, Kirchhof, P & De Caterina, R 2021, 'Reclassification, Thromboembolic, and Major Bleeding Outcomes Using Different mates of Renal Function in Anticoagulated Patients With Atrial Fibrillation: Insights From the PREFER-in-AF and PREFER-in-AF Prolongation Registries', Circulation: Cardiovascular Quality and Outcomes. https://doi.org/10.1161/CIRCOUTCOMES.120.006852

Reclassification, Thromboembolic, and Major Bleeding Outcomes Using Different mates of Renal Function in Anticoagulated Patients With Atrial Fibrillation: Insights From the PREFER-in-AF and PREFER-in-AF Prolongation Registries. / Rohla, Miklos; Pecen, Ladislav; Cemin, Roberto et al.
In: Circulation: Cardiovascular Quality and Outcomes, 2021.

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

TY - JOUR

T1 - Reclassification, Thromboembolic, and Major Bleeding Outcomes Using Different mates of Renal Function in Anticoagulated Patients With Atrial Fibrillation: Insights From the PREFER-in-AF and PREFER-in-AF Prolongation Registries

AU - Rohla, Miklos

AU - Pecen, Ladislav

AU - Cemin, Roberto

AU - Patti, Giuseppe Rocco Salvatore

AU - Siller-Matula, Jolanta M

AU - Schnabel, Renate B

AU - Huber, Kurt

AU - Kirchhof, Paulus

AU - De Caterina, Raffaele

PY - 2021

Y1 - 2021

N2 - The Cockcroft-Gault formula is recommended to determine a renal indication for dose reduction of dabigatran, edoxaban, and rivaroxaban. Nephrology guidelines now recommend the Modification of Diet in Renal Disease (MDRD) and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formulae as more accurate estimates of glomerular filtration rate.

AB - The Cockcroft-Gault formula is recommended to determine a renal indication for dose reduction of dabigatran, edoxaban, and rivaroxaban. Nephrology guidelines now recommend the Modification of Diet in Renal Disease (MDRD) and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formulae as more accurate estimates of glomerular filtration rate.

KW - atrial fibrillation

KW - chronic kidney disease

KW - dabigatran

KW - edoxaban

KW - glomerular filtration rate

KW - atrial fibrillation

KW - chronic kidney disease

KW - dabigatran

KW - edoxaban

KW - glomerular filtration rate

UR - https://iris.uniupo.it/handle/11579/126749

U2 - 10.1161/CIRCOUTCOMES.120.006852

DO - 10.1161/CIRCOUTCOMES.120.006852

M3 - Article

SN - 1941-7713

JO - Circulation: Cardiovascular Quality and Outcomes

JF - Circulation: Cardiovascular Quality and Outcomes

ER -

Rohla M, Pecen L, Cemin R, Patti GRS, Siller-Matula JM, Schnabel RB et al. Reclassification, Thromboembolic, and Major Bleeding Outcomes Using Different mates of Renal Function in Anticoagulated Patients With Atrial Fibrillation: Insights From the PREFER-in-AF and PREFER-in-AF Prolongation Registries. Circulation: Cardiovascular Quality and Outcomes. 2021. doi: 10.1161/CIRCOUTCOMES.120.006852